PHASEBIO PHARMA Average Days of Receivables

Average Days of Receivables of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Average Days of Receivables growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Average Days of Receivables for 2020 was 0.0 (a -100.0% decrease from previous year)
  • Annual Average Days of Receivables for 2019 was 782.69 (a 514.77% increase from previous year)
  • Twelve month Average Days of Receivables ending June 29, 2021 was 575.84 (a 257.08% increase compared to previous quarter)
  • Twelve month trailing Average Days of Receivables increased by 401.71% year-over-year
Trailing Average Days of Receivables for the last four month:
29 Jun '21 30 Mar '20 30 Dec '19 29 Sep '19
575.84 161.26 190.62 114.78
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Average Days of Receivables of PHASEBIO PHARMA

Most recent Average Days of Receivablesof PHAS including historical data for past 10 years.

Interactive Chart of Average Days of Receivables of PHASEBIO PHARMA

PHASEBIO PHARMA Average Days of Receivables for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0
2019 782.69
2018 127.31

Business Profile of PHASEBIO PHARMA

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.